摘要
目的:探讨异丙托溴铵联合人干扰素α2b治疗呼吸道合胞病毒(RSV)感染性肺炎患儿的临床疗效和安全性。方法:选取2023年1月1日~7月31日期间我院收治的100例RSV感染性肺炎患儿作为研究对象,采用随机数字表法分为对照组和观察组,每组50例。两组患儿均给予退热、止咳化痰、保持呼吸道通畅、纠正电解质紊乱等常规治疗,对照组患者给予人干扰素α2b喷雾剂治疗,观察组患者在对照组治疗基础上给予吸入用异丙托溴铵溶液治疗,两组均连续治疗7天。比较两组患儿临床疗效、临床症状改善时间、炎症因子[白介素-18(IL-18)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]、免疫功能(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))及不良反应发生情况。结果:治疗后,观察组患儿临床治疗总有效率(90.00%)高于对照组(74.00%,P<0.05);观察组患儿发热、咳嗽、肺部啰音、呼吸困难临床症状消失时间均短于对照组(P<0.05);两组患儿血清IL-18、IL-6和TNF-α水平均降低,且观察组低于对照组(P <0.05);CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)均升高,且观察组高于对照组(P<0.05);CD8^(+)均降低,且观察组低于对照组(P<0.05);两组患儿不良反应总发生率比较无统计学差异(P>0.05)。结论:异丙托溴铵联合人干扰素α2b治疗RSV感染性肺炎患儿临床疗效较佳,可有效改善炎症因子水平和免疫功能,缓解临床症状,且不会增加不良反应的发生风险。
Objective:To investigate the clinical efficacy and safety of ipratropium bromide combined with recombinant human interferonα2b in the treatment of children with respiratory syncytial virus(RSV)infectious pneumonia.Methods:A total of 100 children with RSV infectious pneumonia treated in a hospital from January 1 to July 31,2023 were selected and divided into the control group and observation group by random number table method,with 50 patients in each group.Both groups were given conventional treatment such as antipyretic,antitussive and expectorant therapies,maintaining airway patency,correcting electrolyte disturbance,etc.The control group was treated with recombinant human interferonα2b spray,and the observation group was treated with ipratropium bromide solution for inhalation in addition to the treatment given in the control group.Both groups were treated for 7 consecutive days.The clinical response,time of improvement in clinical symptoms,inflammatory factors[interleukin-18(IL-18),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],immune function(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+))and adverse reactions were compared between the two groups.Results:After treatment,the total response rate in the observation group(90.00%)was higher than that in the control group(74.00%,P<0.05).The disappearance time of fever,cough,pulmonary rales and dyspnea in the observation group was shorter than that in the control group(P<0.05).The serum levels of IL-18,IL-6 and TNF-αwere decreased in both groups,and were lower in the observation group than those in the control group(P<0.05).CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were increased in both groups, and were higher in the observation group than those in the control group (P<0.05). CD8^(+)was decreased in both groups, and was lower in the observation group than that in the controlgroup (P<0.05). There was no statistically significant difference in the incidence of adverse reactionsbetween the two groups (P>0.05). Conclusion: Ipratropium bromide combined with recombinanthuman interferon α2b exhibited satisfactory clinical efficacy in the treatment of children withRSV infectious pneumonia, which can effectively improve the level of inflammatory factors andimmune function, relieve clinical symptoms, without additional risks of adverse reactions.
作者
冯晓靖
岳瑾
王芳
FENG Xiao-jing;YUE Jin;WANG Fang(Department of Infectious Diseases,Children's Hospital flated to ZhengzhouUniversity,Henan Children's HospitalZhengzhou Children's Hospital,Zhengzhou450000,China)
出处
《中国合理用药探索》
2025年第2期79-84,共6页
Chinese Journal of Rational Drug Use
基金
2021年度河南省医学科技攻关计划联合共建项目(LHGJ20210634)。
关键词
异丙托溴铵
人干扰素α2b
呼吸道合胞病毒
感染性肺炎
疗效
安全性
ipratropium bromide
recombinant human interferonα2b
respiratory syncytial virus
infectious pneumonia
efficacy
safety
